• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Neurological

FDA grants breakthrough nod for Carthera’s SonoCloud-9

June 22, 2022 By Sean Whooley

Carthera SonoCloud

Carthera announced today that it received FDA breakthrough device designation for its SonoCloud-9 system. Paris-based Carthera designed SonoCloud-9 for implantation in a skull window below the skin. Once in place, the device becomes invisible. When activated for a few minutes using a transdermal needle connected to an external control unit, it uses low-intensity pulsed ultrasound to […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance Tagged With: Carthera, FDA

Data shows cost benefits with Pear Therapeutics digital therapeutic for opioid use disorder

June 14, 2022 By Sean Whooley

Pear Therapeutics

Pear Therapeutics (Nasdaq:PEAR) today shared real-world data highlighting low costs with its reSET-O prescription digital therapeutic (PDT). Boston-based Pear Therapeutics’ reSET-O represents the only FDA-authorized PDT for the treatment of opioid use disorder (OUD). According to a news release, results from a 12-month, real-world data study of reSET-O demonstrated reduced healthcare resource utilization and associated […]

Filed Under: Big Data, Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Neurological, Patient Monitoring Tagged With: Pear Therapeutics

Pear Therapeutics reports positive real-world data for chronic insomnia treatment

June 8, 2022 By Sean Whooley

Pear Therapeutics

Pear Therapeutics (Nasdaq:PEAR) today announced real-world data from a trial of its Somryst prescription digital therapeutic (PDT). Data showed that Somryst, the only FDA-authorized PDT for treating chronic insomnia, achieved significant reductions in symptoms of insomnia, anxiety and depression severity both immediately following treatment and at six-months follow-up. Boston-based Pear Therapeutics presented results at the […]

Filed Under: Clinical Trials, Neurological, Technology Tagged With: Pear Therapeutics

Digital therapeutics developer Better Therapeutics names new CEO

June 7, 2022 By Sean Whooley

Better Therapeutics

Better Therapeutics (Nasdaq:BTTX) announced today that it appointed Frank Karbe as its new president and CEO. San Francisco-based Better Therapeutics develops prescription digital therapeutics (PDTs) based on nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases. Karbe will join the company as president and CEO and will serve as a member […]

Filed Under: Business/Financial News, Diabetes, Neurological, Patient Monitoring, Personnel, Technology Tagged With: Better Therapeutics, Personnel, Personnel Moves

FDA approves IND for Ananda Scientific’s PTSD treatment with liquid structure delivery tech

May 18, 2022 By Sean Whooley

Ananda Scientific Logo

Ananda Scientific announced that it received an FDA investigational new drug (IND) approval for a post-traumatic stress disorder (PTSD) treatment. The company will collaborate with the University of Nebraska Medical Center to conduct a clinical trial, led by Dr. Mathew Rizzo, Reynolds Professor and Chair of the UNMC Department of Neurological Sciences and Chief Physician […]

Filed Under: Clinical Trials, Drug-Device Combinations, Food & Drug Administration (FDA), Neurological Tagged With: Ananda Scientific

Digital therapeutics open up new opportunities in medicine

May 5, 2022 By Sean Whooley

Pear Therapeutics reSET_Check_In (1)

A wide range of companies are aiming to make waves through digital therapeutic offerings, and each is doing things differently. “We are seeing tremendous momentum for the DTx industry, with more and more products coming to market and gaining commercial coverage and recent signals from the White House and Congress demonstrating their interest and recognition […]

Filed Under: Business/Financial News, Neurological, Technology Tagged With: Better Therapeutics, dariohealth, Pear Therapeutics, sanofi

How DeepWell is developing video games as tools for treating medical conditions

May 5, 2022 By Sean Whooley

DeepWell Digital Therapeutics Mike Wilson Ryan Douglas

Imagine playing a video game where you are a wizard fighting for good in a magical realm.  You must master control of your mind and body to increase your powers and abilities, creating a forcefield shielding you from enemies and strengthening your counterattack.   In these moments of high anxiety, more control makes you more powerful, […]

Filed Under: Business/Financial News, Featured, Neurological, Technology Tagged With: DeepWell Digital Therapeutics

Impel NeuroPharma rebrands to Impel Pharmaceuticals as part of corporate transformation

April 25, 2022 By Sean Whooley

Impel Neuropharma logo updated

Impel NeuroPharma (Nasdaq:IMPL) announced today that it changed its name to Impel Pharmaceuticals as part of a corporate rebrand. Seattle-based Impel develops proprietary Precision Olfactory Delivery (POD) technology to treat patients suffering from diseases across a range of areas in addition to the central nervous system. The company’s Trudhesa nasal spray for treating migraine in […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Neurological, Otolaryngology Ear, Nose & Throat, Pharmaceuticals Tagged With: Impel NeuroPharma Inc., Impel Pharmaceuticals

FDA grants STeP designation for Pear Therapeutics’ neurobehavioral digital therapeutic

April 13, 2022 By Sean Whooley

Pear Therapeutics

Pear Therapeutics (Nasdaq:PEAR) announced today that it received STeP designation from the FDA for its Pear-010 product candidate. Boston-based Pear Therapeutics designed its Pear-010 prescription digital therapeutic (PDT) candidate to provide a neurobehavioral intervention (virtual reality-delivered pain reduction) to patients 18 and older with acute postoperative and acute postprocedural pain. Get the full story at our […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Neurological, Regulatory/Compliance, Technology Tagged With: FDA, Pear Therapeutics

Pear Therapeutics joins Epic App Orchard to enable monitoring of its digital therapeutics

March 24, 2022 By Sean Whooley

Pear Therapeutics

Pear Therapeutics (Nasdaq:PEAR) announced today that its PearConnect platform is now available in the Epic App Orchard Gallery. By making PearConnect available to healthcare providers through the Epic App Orchard Gallery, the providers who implement the application will be able to access PearConnect within Epic’s electronic health record (EHR) platform, allowing them to monitor patients […]

Filed Under: Big Data, Business/Financial News, Drug-Device Combinations, Featured, Neurological, Patient Monitoring, Technology Tagged With: Pear Therapeutics

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 20
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS